LCAT-expressing adipose cell therapy (Cellgentech)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameLCAT-expressing adipose cell therapy (Cellgentech)
Drug Alias Namegenetically modified adipose cell therapym-ccdPA/lcat
ClassificationCell and gene therapy > Cell therapy
Mechanisms of ActionLCAT gene stimulants
TargetsPhosphatidylcholine-sterol acyltransferase
Therapy Area/IndicationsLecithin Cholesterol Acyltransferase Deficiency
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesChiba UniversityCellgentech
China Registration ClassN/A

Develop Information

Active CompaniesChiba University
Inactive CompaniesN/A
Active IndicationsLecithin Cholesterol Acyltransferase Deficiency
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A